{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:25:59Z","timestamp":1780089959885,"version":"3.54.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jfma.2020.08.026","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T21:43:12Z","timestamp":1601588592000},"page":"926-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology"],"prefix":"10.1016","volume":"120","author":[{"given":"Tsen-Fang","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Tei","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0869-5973","authenticated-orcid":false,"given":"Lin-Fen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-Yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hsiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Jieh","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsiung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Chen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ju","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woan-Ruoh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Tzung","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Cheng","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Ho","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.170516","article-title":"Epidemiology and medication pattern change of psoriatic diseases in Taiwan from 2000 to 2013: a nationwide, population-based cohort study","volume":"45","author":"Wei","year":"2018","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jdermsci.2016.08.535","article-title":"Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based observational study in Taiwan","volume":"84","author":"Wang","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.026_bib3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/acr.23743","article-title":"Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study","volume":"71","author":"Eder","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","article-title":"Prevalence and incidence of psoriasis and psoriatic arthritis","volume":"78","author":"Sewerin","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-017-1497-4","article-title":"The epidemiology of psoriatic arthritis in Israel \u2013 a population-based study","volume":"20","author":"Eder","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsi.2018.06.001","article-title":"Psoriasis in Taiwan: from epidemiology to new treatments","volume":"36","author":"Chiu","year":"2018","journal-title":"Dermatol Sin"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/1346-8138.14097","article-title":"Clinical characteristics of Japanese patients with psoriatic arthritis: comparison with East Asian countries","volume":"45","author":"Yamamoto","year":"2018","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2020.08.026_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40199-014-0080-7","article-title":"The evolution of Taiwan's National Health Insurance drug reimbursement scheme","volume":"23","author":"Hsu","year":"2015","journal-title":"Daru"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib11","doi-asserted-by":"crossref","first-page":"A158","DOI":"10.1016\/j.jval.2015.03.919","article-title":"Disease burden of psoriatic arthritis in Taiwan: a population-based analysis","volume":"18","author":"Wang","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jfma.2017.05.001","article-title":"The current status and unmet needs in the management of psoriatic arthritis: viewpoint from physicians in Taiwan","volume":"117","author":"Li","year":"2018","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dsi.2017.01.002","article-title":"Taiwanese Dermatological Association consensus statement on management of psoriasis","volume":"35","author":"Tsai","year":"2017","journal-title":"Dermatol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jfma.2020.08.026_bib15","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (Eds). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available at: http:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html#h.qmsmbyw3yxsl."},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2014.12.011","article-title":"Guideline panels should not GRADE good practice statements","volume":"68","author":"Guyatt","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jfma.2020.08.026_bib17","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey","volume":"29","author":"van de Kerkhof","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2020.08.026_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00296-015-3377-z","article-title":"Multidisciplinary dermatology\u2013rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review","volume":"36","author":"Cobo-Ib\u00e1\u00f1ez","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jfma.2020.08.026_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3899\/jrheum.170148","article-title":"Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics","volume":"44","author":"Okhovat","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfma.2020.08.026_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-017-0706-0","article-title":"Early recognition and treatment heralds optimal outcomes: the benefits of combined rheumatology\u2013dermatology clinics and Integrative care of psoriasis and psoriatic arthritis patients","volume":"20","author":"Soleymani","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jfma.2020.08.026_bib21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s12325-016-0429-z","article-title":"Points to consider in the foundation of multidisciplinary units for psoriatic arthritis: a Delphi study and a systematic review of the literature","volume":"33","author":"Gratacos-Masmitja","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jfma.2020.08.026_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2020.08.026_bib23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfma.2020.08.026_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jbspin.2018.01.006","article-title":"2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfma.2020.08.026_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.12968\/bjon.2016.25.1.31","article-title":"Shared decision making for patients living with inflammatory arthritis","volume":"25","author":"Palmer","year":"2016","journal-title":"Br J Nurs"},{"key":"10.1016\/j.jfma.2020.08.026_bib27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/PPA.S133222","article-title":"Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs","volume":"11","author":"Lofland","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jfma.2020.08.026_bib28","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/acr.22404","article-title":"Qualifying unmet needs and improving standards of care in psoriatic arthritis","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jfma.2020.08.026_bib29","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-016-3549-5","article-title":"Benefit of health education by a training nurse in patients with axial and\/or peripheral psoriatic arthritis: a systematic literature review","volume":"36","author":"Candelas","year":"2016","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","article-title":"Psoriatic arthritis: epidemiology, diagnosis, and treatment","volume":"5","author":"Liu","year":"2014","journal-title":"World J Orthop"},{"key":"10.1016\/j.jfma.2020.08.026_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jdv.14741","article-title":"Consensus on the management of patients with psoriatic arthritis in a dermatology setting","volume":"32","author":"Gisondi","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2020.08.026_bib34","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2020.08.026_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2020.08.026_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.13599","article-title":"Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study","volume":"173","author":"Chiu","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib38","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10279","article-title":"Comorbidities in patients with psoriatic arthritis","volume":"8","author":"Haddad","year":"2017","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib39","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000588","article-title":"Real-world burden of comorbidities in US patients with psoriatic arthritis","volume":"3","author":"Shah","year":"2017","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00296-017-3895-y","article-title":"Addressing comorbidities in psoriatic disease","volume":"38","author":"Patel","year":"2018","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.026_bib42","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3899\/jrheum.141112","article-title":"Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative","volume":"42","author":"Roubille","year":"2015","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"10012","key":"10.1016\/j.jfma.2020.08.026_bib44","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"5 Suppl. 101","key":"10.1016\/j.jfma.2020.08.026_bib45","first-page":"S73","article-title":"Implementing the findings of the TICOPA trial in clinical practice: challenges in implementation and how information technology can bridge the gap","volume":"34","author":"Coates","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.026_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016619","article-title":"Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry","volume":"7","author":"Rahman","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-017-1277-1","article-title":"Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.jfma.2020.08.026_bib49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease","year":"2017","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.jfma.2020.08.026_bib51","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3899\/jrheum.150165","article-title":"The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis","volume":"42","author":"Geijer","year":"2015","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr.22576","article-title":"Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jfma.2020.08.026_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D'Angelo","year":"2017","journal-title":"Open Access Rheumatol"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jbspin.2017.11.001","article-title":"Treatment strategies for psoriatic arthritis","volume":"85","author":"Schemoul","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.jfma.2020.08.026_bib55","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","article-title":"Predictors of response to intra-articular steroid injection in psoriatic arthritis","volume":"49","author":"Eder","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjd.14061","article-title":"Psoriasis flare with corticosteroid use in psoriatic arthritis","volume":"174","author":"Coates","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib57","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib59","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/eye.2008.198","article-title":"Methotrexate: an option for preventing the recurrence of acute anterior uveitis","volume":"23","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2009","journal-title":"Eye (Lond)"},{"issue":"1\u20132","key":"10.1016\/j.jfma.2020.08.026_bib60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000443129","article-title":"Methotrexate for inflammatory bowel diseases \u2013 new developments","volume":"34","author":"Herfarth","year":"2016","journal-title":"Dig Dis"},{"issue":"7","key":"10.1016\/j.jfma.2020.08.026_bib61","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","article-title":"Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study","volume":"35","author":"Combe","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"12","key":"10.1016\/j.jfma.2020.08.026_bib62","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"Pt 3A","key":"10.1016\/j.jfma.2020.08.026_bib63","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-Del-Castillo","year":"2000","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.026_bib65","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib66","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004836-200308000-00006","article-title":"Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy","volume":"37","author":"Prajapati","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.026_bib68","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3341\/kjo.2012.26.1.21","article-title":"Clinical outcomes of cyclosporine treatment for noninfectious uveitis","volume":"26","author":"Lee","year":"2012","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib70","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/bjophthalmol-2015-307251","article-title":"Topical cyclosporine A 0.05% for recurrent anterior uveitis","volume":"100","author":"Prabhu","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.52.2.172","article-title":"Cyclosporin for refractory ulcerative colitis","volume":"52","author":"Loftus","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2020.08.026_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.jfma.2020.08.026_bib73","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib74","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjd.18331","article-title":"Sustained efficacy of secukinumab in subjects with moderate-to-severe palmoplantar psoriasis: 2\u00b75-year results from GESTURE, a randomized, double-blind, placebo-controlled trial","volume":"182","author":"Gottlieb","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13006","article-title":"Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study","volume":"32","author":"Rompoti","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/imt-2017-0149","article-title":"A review of ustekinumab in the treatment of psoriatic arthritis","volume":"10","author":"Roberts","year":"2018","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","article-title":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis","volume":"49","author":"Lu","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib79","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2015.09.004","article-title":"Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis","volume":"45","author":"Ungprasert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jfma.2020.08.026_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.026_bib81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-018-0898-2","article-title":"Role of methotrexate in the management of psoriatic arthritis","volume":"78","author":"Elmamoun","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib82","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","article-title":"Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry","volume":"39","author":"Hernandez","year":"2019","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib83","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib84","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.jfma.2020.08.026_bib85","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","article-title":"Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature","volume":"35","author":"Reddy","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.jfma.2020.08.026_bib86","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","article-title":"Switching between biological treatments in psoriatic arthritis: a review of the evidence","volume":"17","author":"Costa","year":"2017","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.026_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Comp\u00e1n","year":"2017","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.026_bib90","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-014-2742-8","article-title":"Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort","volume":"34","author":"Bremander","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jfma.2020.08.026_bib91","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","article-title":"Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: results from the DANBIO registry","volume":"74","author":"H\u00f8jgaard","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.026_bib92","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","article-title":"Obesity and the risk of psoriatic arthritis: a population-based study","volume":"71","author":"Love","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jfma.2020.08.026_bib93","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.026_bib94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.026_bib95","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2020.08.026_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.09235","article-title":"Rehabilitation in psoriatic arthritis","volume":"83","author":"Lubrano","year":"2009","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib97","first-page":"41","article-title":"Psoriatic arthritis and arthroplasty: a review of the literature","volume":"66","author":"lofin","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.026_bib98","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jaad.2016.06.014","article-title":"From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis","volume":"75","author":"Choi","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.026_bib99","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/art.40149","article-title":"2017 American College of Rheumatology\/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"69","author":"Goodman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.026_bib100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09273948.2012.723107","article-title":"Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis","volume":"21","author":"Cordero-Coma","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfma.2020.08.026_bib101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jfma.2020.08.026_bib102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","article-title":"Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-\u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis","volume":"76","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jfma.2020.08.026_bib103","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","article-title":"Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence","volume":"48","author":"Mouyis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jfma.2020.08.026_bib104","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/andr.12366","article-title":"The impact of drugs on male fertility: a review","volume":"5","author":"Semet","year":"2017","journal-title":"Andrology"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620304009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620304009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:43:45Z","timestamp":1760539425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620304009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0929664620304009"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.026","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}